Design, optimization and in-vitro study of folic acid conjugated-chitosan functionalized PLGA nanoparticle for delivery of bicalutamide in prostate cancer

Powder Technology

Volumn 283, Issue , 2015, Pages 234-245

  Dhas, Namdev L ^a   Ige, Pradum P ^a   Kudarha, Ritu R ^a  

^a R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Box BehnkenRSM; DU145 cell line; Folic acid chitosan conjugate; PLGA nanoparticle; Prostate cancer

Indexed keywords

CELL CULTURE; CHITIN; CHITOSAN; COPOLYMERS; NANOPARTICLES; ORGANIC ACIDS; ORGANIC POLYMERS; UROLOGY;

BOX-BEHNKENRSM; DU-145 CELLS; FOLIC ACIDS; PLGA NANOPARTICLES; PROSTATE CANCERS;

DISEASES;

BICALUTAMIDE; CHITOSAN; FOLIC ACID; NANOPARTICLE; PLACEBO; POLYGLACTIN;

ADSORPTION; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG COATING; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; FREEZE DRYING; HEMOLYSIS; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INFRARED SPECTROSCOPY; PARTICLE SIZE; PH; PRECIPITATION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SCANNING ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 84930683716     PISSN: 00325910     EISSN: 1873328X     Source Type: Journal    
DOI: 10.1016/j.powtec.2015.04.053     Document Type: Article

References (45)

1. Laverman P., Carstens M.G., Storm G., Moghimi S.M. Recognition and clearance of methoxy poly (ethylene glycol) 2000-grafted liposomes by macrophages with enhanced capacity: implications in experimental and clinical oncology. Biochem. Biophys Acta. 2001, 1523:227-229.
2. Gronberg H. Prostate cancer epidemiology. Lancet 2003, 361:859-864.
3. Fizazi K., Navone N.M. Preclinical models of prostate cancer. Bull. Cancer 2005, 92:129-141.
4. Kumbhar D.D., Pokharkar V.B. Engineering of a 563 nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: physicochemical investigations. Colloids Surf. A Physicochem. Eng. Asp. 2013, 416:32-42.
5. Masiello D., Cheng S., Bubley G.J., Lu M.L., Balk S.P. Bicalutamide functions as androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J. Biol. Chem. 2002, 277:26321-26326.
6. Milone M.R., Pucci B., Bruzzese F., Carbone C., Piro G., Costantini S., Capone F., Leone A., Di Gennaro E., Caraglio M., Budillon A. Acquired resistance to zolendronic acid and the parallel acquisition of an aggressive phenotype are mediated by P-38-MAP kinase activation in prostate cancer cells. Cell Death Dis. 2013, 4:1-11.
7. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000, 11:265-283.
8. Hodgson M.C., Astapova I., Hollenberg A.N., Balk S.P. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res. 2007, 67:8388-8395.
9. Li C., Le Y., Chen J.F. Formulation of bicalutamide nanodispersion for dissolution rate enhancement. Int. J. Pharm. 2011, 404:257-263.
10. Gaumet M., Vargas A., Gurny R., Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm. 2008, 69:1-9.
11. Cho H.S., Dong Z., Pauletti G.M., Zhang J., Xu H., Gu H., Wang L., Ewing R.C., Huth C., Wang F., Shi D. Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment. ACS Nano 2010, 4:5398-5404.
12. Steichen S.D., Caldorera-Moore M., Peppas N.A. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharm. Sci. 2013, 48:416-427.
13. Van Amersfoort E.S., Van Strijp J.A.G. Evaluation of a flow cytometric fluorescence quenching assay of phagocytosis of sensitized sheep erythrocytes by polymorphonuclear leukocytes. Cytometry 1994, 17:294-301.
14. Vauthier C., Dubernet C., Fattal E., Pinto-Al Phandry H., Couvreur P. Poly(alkyl cyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Deliv. Rev. 2003, 55:519-548.
15. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55:329-347.
16. Joshi S.A., Chavhan S.S., Sawant K.K. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur. J. Pharm. Biopharm. 2010, 76:189-199.
17. Fredenberg S., Wahlgren M., Reslow M., Axelsson A. The mechanisms of drug release in poly (lactide-co-glycolic acid) based drug delivery systems - a review. Int. J. Pharm. 2011, 415:34-52.
18. Danhier F., Ansorena E., Silva J.M., Coco R., Breton A.L., Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 2012, 161:505-522.
19. Atyabi F., Ghahremani M.H., Dinarvand R. Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: in vitro and in vivo studies. Eur. J. Pharm. Biopharm. 2013, 84(1):63-71.
20. Sah H., Thoma L.A., Desu H.R., Sah E., Wood G.L. Concept and practices used to develop functional PLGA based nanoparticulate systems. Int. J. Nanomedicine 2013, 8:747-765.
21. Furman C., Le Broc-Ryckewaert D., Carpentier R., Lipka E., Daher S., Vaccher C., Betbeder D. Development of innovative paclitaxel-loaded small PLGA nanoparticles: study of their antiproliferative activity and their molecular interactions on prostatic cancer cells. Int. J. Pharm. 2013, 454:712-719.
22. Chakravarti S.S., Robinson D.H. Enhanced cellular association of paclitaxel delivered in chitosan - PLGA particles. Int. J. Pharm. 2011, 409:111-120.
23. Shapira A., Livney Y.D., Broxterman H.J., Assaraf Y.G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat. 2011, 14:150-163.
24. Mora-Huertas C.E., Fessi H., Elaissari A. Influence of process and formulation parameters on the formation of submicron particles by solvent displacement and emulsification-diffusion methods critical comparison. Adv. Colloid Interf. Sci. 2011, 163:90-122.
25. Moghimi S.M., Hunter A.C., Murray J.C. Long circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
26. Stella B., Arpicco S., Peracchia M.T., Desmaele D., Hoebeke J., Renoir M., D'Angelo J., Cattel L., Couvvreur P. Design of folic acid conjugated nanoparticles for drug targeting. J. Pharm. Sci. 2000, 89:1452-1464.
27. Pan J., Feng S.S. Targeting and imaging cancer cells by folate-decorated, quantum dots (QDS) - loaded nanoparticles of biodegradable polymers. Biomaterials 2009, 30:1176-1183.
28. Zu Y., Zhao Q., Zhao X., Zu S., Meng Li. Process optimization for the preparation of oligomycin-loaded folate-conjugated chitosan nanoparticles as a tumor-targeted drug delivery system using a two-level factorial design method. Int. J. Nanomedicine 2011, 6:3429-3441.
29. Chawan M., Kwanchanok V.P., Nuttaporn P. Preparation of folate-conjugated pluronic F127/chitosan core-shell nanoparticles encapsulating doxorubicin for breast cancer treatment. J. Nanomater. 2012, 2012:1-11.
30. Saez A., GuzmaÂn M., Molpeceres J., Aberturas M.R. Freeze-drying of polycaprolactone and poly (d, l-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur. J. Pharm. Biopharm. 2000, 50:379-387.
31. Abdelwahed W., Degobert G., Stainmesse S., Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev. 2006, 58:1688-1713.
32. Danquah M., Fujiwara T., Mahato R.I. Self-assembling methoxypoly (ethylene glycol)-b poly (carbonate-co-l-lactide) blocks copolymers for drug delivery. Biomaterials 2010, 31:2358-2370.
33. McGowen R., Biliran H., Sager R., Sheng S. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res. 2000, 60:4771-4778.
34. Okamoto R., Delansoren R., Wakimoto N., Doan N.B., Akagi T., Shen M., Ho Q.C., Said J.W., Koeffer H.P. Inecalcitol, an analog of 1α, 25(OH)2 D3, induced growth arrest of androgen dependent prostate cancer cells. Int. J. Cancer 2012, 130:2464-2473.
35. Sharma G., Modgil A., Layek B., Arora K., Sun C., Law B., Singh J. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection. J. Control. Release 2013, 167:1-10.
36. Zhang J., Liang J., Tian Z., Chen L., Subirade M. Preparation and in vitro evaluation of calcium-induced soy protein isolate nanoparticles and their formation mechanism study. Food Chem. 2012, 133:390-399.
37. Parveen S., Sahoo S.K. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur. J. Pharmacol. 2011, 670:372-383.
38. Ige P.P., Baria R.K., Gattani S.G. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids Surf. B: Biointerfaces 2013, 108:366-373.
39. Jain S., Mittal A., Jain A., Mahajan R.R., Singh D. Cyclosporin - a loaded PLGA nanoparticle: preparation, optimization, in-vitro characterization and stability studies. Curr. Nanosci. 2010, 6(4):1-10.
40. Li P., Wang Y., Zeng F., Chen L., Peng Z., Kong L.X. Synthesis and characterization of folate conjugated chitosan and cellular uptake of its nanoparticles in HT-29 cells. Carbohydr. Res. 2011, 346:801-806.
41. Yang S.J., Lin F.H., Tsai K.C., Wei M.F., Tsai H.M., Wong J.M., Shieh M.J. Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin ix accumulation in colorectal cancer cells. Bioconjug. Chem. 2010, 21:679-689.
42. Zweers M.L.T., Grijpma D.W., Engbers G.H.M., Feijen J. The preparation of monodisperse biodegradable polyester nanoparticles with a controlled size. J. Biomed. Mater. Res. B Appl. Biomater. 2003, 66B:559-566.
43. Jeffery H., Davis S.S., O'Hagan D.T. The preparation and characterization of poly (lactide co-glycolide) microparticles. I. Oil-in-water emulsion solvent evaporation. Int. J. Pharm. 1991, 77:169-175.
44. Yang Y.Y., Chung T.S., N.P.N Morphology, drug distribution and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double emulsion solvent extraction/evaporation method. Biomaterials 2001, 22:231-241.
45. Motwani S.K., Chopra S., Talegaonkar S., Kohli K., Ahmad F.J., Khar R.K. Chitosan sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimization and in vitro characterization. Eur. J. Pharm. Biopharm. 2008, 68:513-525.